NLM Logo

PE regimen MeSH Supplementary Concept Data 2024


MeSH Supplementary
PE regimen
Unique ID
C075609
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/C075609
Registry Number
0
Heading Mapped to
*Antineoplastic Combined Chemotherapy Protocols
Cisplatin
Epirubicin
Frequency
12
Note
chemotherapy protocol consisting of above cpds; used in the treatment of symptomatic advanced non-small-cell lung cancer; PE protocol consists of CISPLATIN & ETOPOSIDE
Source
Cancer Chemother Pharmacol 1992;30(3):212-4
Date of Entry
1992/08/12
Revision Date
2000/11/30
PE regimen Preferred
page delivered in 0.001s